GAM
AGIO icon

Griffin Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Griffin Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,382
Closed -$201K – 229
2025
Q4 		$201K Buy
+7,382
New +$259K 0.02% 226

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Griffin Asset Management's AGIO Position: Q1 2026 in Review

Griffin Asset Management sold out of Agios Pharmaceuticals (AGIO) in Q1 2026, closing a stake of 7,382 shares — an estimated $201K sold.

Griffin Asset Management first reported a position in AGIO in Q4 2025 and held it in 1 quarter. The position peaked at $201K in Q4 2025. 234 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Griffin Asset Management reported no remaining Agios Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Griffin Asset Management sold 7,382 Agios Pharmaceuticals shares in Q1 2026, an estimated $201K.
  • Griffin Asset Management first reported a position in Agios Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Griffin Asset Management's Agios Pharmaceuticals position peaked at $201K in Q4 2025.
  • 234 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Griffin Asset Management's 13F filing for Q1 2026, filed 30 Apr 2026.